An inexpensive drug often used to treat obsessive-compulsive disorder and depression may reduce patients’ risk of Covid-19 hospitalization, a new study in the Lancet medical journal found Wednesday, providing a potentially cheaper alternative to current therapies like monoclonal antibodies.
